Brkovic Alexandre, Sirois Martin G
Research Center, Montreal Heart Institute, Department of Pharmacology, Université de Montréal, Montreal, QC, Canada.
J Cell Biochem. 2007 Feb 15;100(3):727-37. doi: 10.1002/jcb.21124.
We previously reported that vascular endothelial growth factor (VEGF) increases vascular permeability through the synthesis of endothelial platelet-activating factor (PAF), while others reported the contribution of nitric oxide (NO). Herein, we addressed the contribution of VEGF receptors and the role played by PAF and NO in VEGF-induced plasma protein extravasation. Using a modified Miles assay, intradermal injection in mice ears of VEGF-A(165), VEGF-A(121), and VEGF-C (1 microM) which activate VEGFR-2 (Flk-1) receptor increased vascular permeability, whereas a treatment with VEGFR-1 (Flt-1) analogs; PlGF and VEGF-B (1 microM) had no such effect. Pretreatment of mice with PAF receptor antagonist (LAU8080) or endothelial nitric oxide synthase (eNOS) inhibitor (L-NAME) abrogated protein extravasation mediated by VEGF-A(165). As opposed to PAF (0.01-1 microM), treatment with acetylcholine (ACh; up to 100 microM; inducer of NO synthesis) or sodium nitroprusside (SNP; up to 1 microM; NO donor) did not induce protein leakage. Simultaneous pretreatment of mice with eNOS and protein kinase A (PKA) inhibitors restored VEGF-A(165) vascular hyperpermeability suggesting that endogenous NO synthesis leads to PKA inhibition, which support maintenance of vascular integrity. Our data demonstrate that VEGF analogs increase vascular permeability through VEGFR-2 activation, and that both endogenous PAF and NO synthesis contribute to VEGF-A(165)-mediated vascular permeability. However, PAF but not NO directly increases vascular permeability per se, thereby, suggesting that PAF is a direct inflammatory mediator, whereas NO serves as a cofactor in VEGF-A(165) proinflammatory activities.
我们之前报道过,血管内皮生长因子(VEGF)通过合成内皮血小板活化因子(PAF)增加血管通透性,而其他人报道了一氧化氮(NO)的作用。在此,我们探讨了VEGF受体的作用以及PAF和NO在VEGF诱导的血浆蛋白外渗中所起的作用。使用改良的迈尔斯试验,在小鼠耳部皮内注射激活VEGFR-2(Flk-1)受体的VEGF-A(165)、VEGF-A(121)和VEGF-C(1微摩尔)可增加血管通透性,而用VEGFR-1(Flt-1)类似物PlGF和VEGF-B(1微摩尔)处理则没有这种效果。用PAF受体拮抗剂(LAU8080)或内皮型一氧化氮合酶(eNOS)抑制剂(L-NAME)预处理小鼠可消除VEGF-A(165)介导的蛋白外渗。与PAF(0.01 - 1微摩尔)不同,用乙酰胆碱(ACh;高达100微摩尔;NO合成诱导剂)或硝普钠(SNP;高达1微摩尔;NO供体)处理不会诱导蛋白渗漏。用eNOS和蛋白激酶A(PKA)抑制剂同时预处理小鼠可恢复VEGF-A(165)引起的血管高通透性,这表明内源性NO合成导致PKA抑制,从而支持血管完整性的维持。我们的数据表明,VEGF类似物通过激活VEGFR-2增加血管通透性,并且内源性PAF和NO合成均有助于VEGF-A(165)介导的血管通透性。然而,PAF而非NO本身直接增加血管通透性,因此,表明PAF是一种直接的炎症介质,而NO在VEGF-A(165)的促炎活性中起辅助因子的作用。